TTrialPathMatch Me to Trials
← Back to trials
RecruitingSpinal Cord Injuries

Transcutaneous Spinal Cord Stimulation Combined With 4-Aminopyridine and Intensive Rehabilitation in SCI

Eligible age

18–75 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this prospective, single-arm pilot feasibility study is to evaluate the safety, feasibility, and preliminary functional outcomes of combining transcutaneous spinal cord stimulation (TSS), dalfampridine (4-aminopyridine), and intensive rehabilitation in adults with chronic spinal cord injury (SCI). The primary research question is whether this combined treatment approach can be safely and feasibly implemented in an outpatient neurorehabilitation setting. The study will also explore whether participants demonstrate improvements in upper and lower extremity motor function, muscle strength, walking ability, balance, and functional mobility following the intervention. Eight adults with chronic spinal cord injury will participate in a 12-week rehabilitation program at TRYAbility NeuroRecovery Center. Participants will attend approximately three treatment sessions per week, consisting of 60 minutes of physical therapy and 60 minutes of occupational therapy combined with noninvasive transcutaneous spinal cord stimulation using the ANEUVO ExaStim Stimulation System. All participants will be receiving dalfampridine prescribed by their treating physicians as part of routine medical care. The research team will not prescribe, administer, or adjust medication dosages. The primary outcomes will focus on participant recruitment, treatment attendance, intervention tolerability, and adverse events to assess the feasibility and safety of the combined approach. Secondary exploratory outcomes will examine changes in upper extremity motor function, hand dexterity, walking speed, walking endurance, balance, and functional mobility. Participants will undergo standardized clinical assessments at baseline, week 6, and week 12 to evaluate changes in functional performance over time. The findings will provide preliminary evidence regarding the feasibility, safety, and potential functional benefits of integrating spinal cord stimulation, physician-prescribed dalfampridine, and intensive rehabilitation. Results will help inform the design of larger controlled clinical trials investigating combined treatment approaches for motor recovery following chronic spinal cord injury.

Sponsor: TryAbility LLC

You may not qualify if…

  • ✕ History of uncontrolled seizure disorder.
  • ✕ Contraindication to 4-aminopyridine (dalfampridine).
  • ✕ Uncontrolled cardiovascular disease.
  • ✕ Presence of implanted electrical medical devices, including pacemakers or neurostimulators.
  • ✕ Pregnancy.
  • ✕ Severe pressure injuries that prevent safe electrode placement.
  • ✕ Known or suspected significant cognitive impairment, dementia, intellectual disability, or other neurological or psychiatric conditions that interfere with comprehension of study requirements or the ability to complete study assessments.

Where it's recruiting

Illinois

Downers Grove

Source: ClinicalTrials.gov · NCT07922122 · last updated 2026-11-06

Transcutaneous Spinal Cord Stimulation Combined With 4-Aminopyridine a · TrialPath